Skip Navigation


NDT Advance Access originally published online on April 29, 2009
Nephrology Dialysis Transplantation 2009 24(10):3132-3137; doi:10.1093/ndt/gfp201
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/10/3132    most recent
gfp201v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Witzig, T. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Witzig, T. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

Morie A. Gertz1, Nelson Leung2, Martha Q. Lacy1, Angela Dispenzieri1, Steven R. Zeldenrust1, Suzanne R. Hayman1, Francis K. Buadi1, David Dingli1, Philip R. Greipp1, Shaji K. Kumar1, John A. Lust1, S. Vincent Rajkumar1, Stephen J. Russell1 and Thomas E. Witzig1

1 Division of Hematology 2 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

Correspondence and offprint requests to: Morie A. Gertz; E-mail: gertz.morie{at}mayo.edu



  Abstract

Background. The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.

Methods. Kaplan–Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 years. Outcome measurements were needed for renal replacement therapy and survival.

Results. Among patients presenting with renal AL, 42% ultimately received renal replacement therapy versus 5% of patients who did not have this presentation. Patients with renal amyloid who received dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with {lambda} light chain amyloid were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with {kappa} light chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26% of patients with AL ultimately received renal replacement therapy versus 42% of patients who presented with renal AL specifically.

Conclusions. Presenting 24-h urine protein loss and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence of {lambda} light chain amyloid predicts the increased likelihood of renal involvement.

Keywords: amyloidosis; dialysis; immunoglobulin light chains; proteinuria; renal failure

Received for publication: 16.12.08
Accepted in revised form: 7. 4.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Ronco and P. Aucouturier
Renal involvement in AL amyloidosis: the facts, the promise and the hope
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 2967 - 2969.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.